Identifying adult gastrointestinal stem cells
Stem cells are undifferentiated cells able to both selfrenew and differentiate to produce nonrenewing progenitors as well as terminally differentiated effector cells. In the adult gastrointestinal system, stem cells generally considered to be tissue-specific are able to give rise only to progeny cells corresponding to their tissue of origin, such as liver, stomach, and small/large bowel. However, for the most part, phenotypic markers for these tissuespecific stem cell populations remain ill-defined, and can only be identified by positional or anatomical criteria; these include liver (Forbes et al., 2002; Wang et al., 2003) , pancreas (Bonner-Weir and Sharma, 2002; Murtaugh and Melton, 2003) , and intestinal stem cells, which are believed to reside near the bottom of the intestinal crypts (Bjerknes and Cheng, 1999; Spradling et al., 2001) . The prospective identification of highly purified stem cell populations from the adult gastrointestinal tissues in which they persist, and the development of clonogenic assays for their function will be essential for understanding their plasticity, regenerative capacity, as well as their role in tumorigenesis.
Gut development occurs through an interaction of two key signaling pathways, the TGF-b (Sporn and Roberts, 1988 Roberts, , 1990 Moses et al., 1991; Liu et al., 2004; Seoane et al., 2004) and Wnt signaling pathways as well as transcriptional regulators of endoderm formation, such as members of the fibroblast growth factors (FGF), Gata, and Forkhead transcription factor families (Wells and Melton, 1999; Matsumoto et al., 2002; Stainier, 2002 Stainier, , 2005 Mishra et al., 2004) . Remarkably, this complex sequence of signals is highly conserved across the phyla from Caenorhabditis elegans, Drosophila, sea urchins, ascidians, Xenopus, zebrafish, the chick, and the mouse (Clements et al., 2001) . The primitive gut in vertebrates is derived from endoderm during late blastula to gastrulation, where it converges toward the midline and extends to cover the entire anteroposterior (AP) extent of the embryo, subsequently forming a hollow tube divided into three somewhat arbitrary divisions, the foregut, midgut, and hindgut (Horne-Badovinac et al., 2003) . Each of these divisions will give rise to specialized regions such as the thyroid, lungs, liver, pancreas, stomach, and small intestine, (Houssaint, 1981; Slack, 1995; Zaret, 1996; Mishra et al., 1998) ; lineage and cell differentiation are highly dependent on pathways such as TGF-b.
The TGF-b superfamily signals are conveyed through serine/threonine kinase receptors to specific intracellular mediators known as the Smad proteins (Roberts, 1999; Shi and Massague, 2003; Liu et al., 2004) . Vertebrates possess at least eight Smad proteins falling into three functional classes: (i) receptor activated Smads (RSmads): Smad1, Smad2, Smad3, Smad5, and Smad8; (ii) comediator Smads: Smad4 and Smad10; (iii) Inhibitory Smads: Smad6 and Smad7. R-Smads and Smad4 are predominantly cytoplasmic. Their activity is modulated by adaptors such as SARA in the case of Smad2, ELF as in the case of Smad3 and Smad4 as well as functional interactions with multiple signal transduction pathways (Tsukazaki et al., 1998; Tang et al., 2003) . Other intracellular regulators of Smad function include microtubules that serve as cytoplasmic sequesters, controlling Smad2 association and phosphorylation by TGF-b receptor I (TbRI). Smad2 and Smad4 are tumor suppressors in humans (Dong et al., 2000) . Adaptor proteins play a critical role for the proper control of Smad access to the receptors for activation at the cell membrane for facilitating TGF-b functions such as growth, differentiation, vascular remodeling, and cell fate specification. It is becoming clear that assembly of signaling components for the effective execution of the Smad signal transduction pathway requires the identification of physiologically significant adaptor proteins that facilitate TGF-b signaling. This is of great importance as these proteins generate the tight regulation required for subcellular localization and Smad phosphorylation by the receptor. Studies are now emerging demonstrating a prominent role of the TGFb pathway in gastrointestinal cell progenitor cell formation as well as its complex role in differentiation, with disruptions resulting in cancer (Figure 1) .
Although complex and largely uncharacterized, organ formation is heralded by gradients of TGF-b and Wnt down the gut with concomitant expression of homeobox genes, such as Pdx1, which is critical for pancreas formation in humans and mice, and cdx2 for hindgut development in humans, mice, and Drosophila (Lengyel and Liu, 1998; Roberts, 2000) . Another example is the regulation of endodermal labial expression, and gut differentiation by mesodermal Ubx through bone morphogenetic protein (BMP)/TGF-b and Wnt gradients. Labial regulates the differentiation of a specialized set of endodermal cells, and defects in labial expression result in aberrant gut morphology, which is remarkably similar to the phenotype of b-Spectrin mutants that include the TGF-b regulated b-Spectrin adaptor ELF (Dubreuil et al., 2000 (Dubreuil et al., , 2001 Tang et al., 2003 Tang et al., , 2005 . The abnormalities in gut epithelial cell morphology in elf À/À mutant embryos include, severely flattened gut epithelial cells with loss of villi. A marked distortion in Na-K, ATPase, MAP-2 (microtubule associated protein), and actin with increased Vimentin, decreased
Figure 1 TGF-b ligands signal through distinct receptors and Smads that are modulated by adaptor proteins and ubiquitinators. TGF-b binds to serine threonine kinase receptor complexes that phosphorylate R-Smads as well as adaptor proteins such as ELF. RSmads, ELF, and Smad4 form a heteromeric complex with Smad4, and translocate to the nucleus, activating target genes. At all levels, Smad modulation occurs through adaptor proteins as well as E3 ligases such as PRAJA and Smurfs, generating the diverse and complex signals required for gastrointestinall cell differentiation. Arrows indicate signal flow and are colour coded: red for ligand and receptor activation, olive green for Smad and receptor inactivation, light green for Smad activation and formation of a transcriptional complex, and blue for Smad nucleocytoplasmic shuttling. Phosphate groups and ubiqutin are represented by green and red circles, respectively
Role of TGF-b and Wnt signaling L Mishra et al E-cadherin, but normal Ankyrin B and G expression were observed in the elf À/À gut epithelial cells: Na-K, ATPase appeared irregular and punctate intracellularly, and absent at the plasma membrane in the elf À/À cells. In these mutants, despite aberrant gut morphology, organelle formation is intact in elf À/À cells, indicating an important role for TGF-b signaling through ELF in conferring partial epithelial cell polarity. In this scenario, the establishment of spatial coordinates during differentiation of polarized cells involves a positional cue from cadherins that results in targeting of the abSpectrin tetramer to a discrete plasma membrane domain. The spectrin tetramer is then able to capture and stabilize additional membrane interacting proteins, forming the characteristic profile of a polarized membrane domain, thus facilitating acquisition of proteins such as the basolateral Na-K ATPase. These studies indicate the requirement of a TGF-b regulated bspectrin for this interaction. The lack of polarized distribution of the Na-K ATPase in the elf b-spectrin mutant phenotype resembles the Drosophila b-spectrin mutant that is in turn reminiscent of the Drosophila labial phenotype, particularly in the gut. Control of the homeotic gene labial is dependent upon extracellular gradients of wingless and decapentaplegic (the Drosophila homolog of TGF-b during embryogenesis), suggesting that TGF-b/ELF interactions are important for gut epithelial cell formation and are conserved through evolution.
The first sign of a liver bud is seen around 8.5 days postcoitum in the mouse when FGFs and BMPs secreted from surrounding mesenchyme of the septum transversum induce a thickening of the ventral floor of the foregut endoderm (Le Douarin and Houssaint, 1967; Houssaint, 1981; Tosh and Strain, 2005) . This region then produces cells destined to become hepatoblasts, bipotential cells committed to fetal hepatocytes and biliary epithelial cells. Hepatoblasts express alphafetoprotein (AFP) and albumin and later both hepatocyte (AFP) and biliary (cytokeratins 7 and 19) lineages. In adult human tissues, these hepatic progenitor cells (or mouse oval cells) are immature epithelial cells found residing in the smallest terminal branches of the biliary tree, the canals of Hering, that connect the interhepatocytic bile canaliculi with the bile ducts in the portal tract (Roskams et al., 2003; Mishra et al., 2004) . In hepatocarcinogenesis, human hepatic progenitor cells can give rise to hepatocellular carcinoma as well as cholangiocarcinomas (Shafritz and Hadziyannis, 1987; Theise et al., 1999) . In these models, a periportal population of small 'primitive' oval epithelial cells proliferates in association with or before hepatocyte multiplication. Mouse oval cells express phenotypic markers of both (immature) hepatocytes (such as afetoprotein, hepar-1, and albumin), and hematopoietic markers (such as the receptor for stem cell factor (c-kit), CD34) and bile duct cells (such as biliary-type CKs, oval cell marker (OV) 6, CK7, CK14, and CK19) (Lemire et al., 1991) . Interestingly, bone marrow (BM)-derived stem cells can give rise to hepatocytes, oval cells, and bile duct cells. Similar mechanisms have been described in human liver (Petersen et al., 1999) perhaps by fusion (Alison et al., 2000; Korbling et al., 2002) (Figure 2) .
Modulation of biliary and liver epithelial cell morphogenesis is prominent in TGF-b signaling by Smad proteins. Heterozygous inactivation of both Smad2 and Smad3, which are transcriptional mediators of TGF-b signaling, causes fetal liver hypoplasia. Addition of HGF to Smad2 þ /À , Smad3 þ /À mutant liver explants restored their growth in vitro, correcting levels of integrin-b that were depressed in the Smad2
þ /À livers, indicating that HGF and TGF-b provide parallel growth signals (Weinstein et al., 2001) . Recruitment of Smads to the receptor and consequent activation is regulated by a number of adaptor molecules such as SARA, Filamin, Microtubules and ELF (Dong et al., 2000; Wrana, 2000; Tang et al., 2003) . Disruption of the b-Spectrin ELF in mice leads to disruption of TGF-b signaling, resulting in a phenotype similar to Smad2
þ /À mutant mice of midgestational death due to gastrointestinal, liver, neural and heart defects, and loss of intrahepatic bile ducts. In the elf mutants, TGF-b stimulates phosphorylation and association of ELF with Smad3 and Smad4, followed by nuclear translocation. ELF deficiency results in mislocalization of Smad3, Smad4, and loss of TGF-b dependent transcription (Tang et al., 2003) . Interestingly, while liver lineage is established, hepatocytes are poorly formed, and liver architecture is lost with an absence of primitive bile ducts as in the Smad2
þ /À mutants. Bile duct formation can be induced in liver explant cultures treated with TGF-b. In this model of haplo-insufficiency, the addition of TGF-b appears sufficient to drive up Smad2 and Smad3 levels and the formation of a limiting plate and bile ducts. Moreover, PRAJA, a TGF-b/BMP regulated protein is expressed in hepatoblasts and modulates ELF and Smad3 adding to the complexity of TGF-b signaling in the gut . Thus, emerging new data indicate that TGF-b is important for stem cell transitioning to a progenitor cell phenotype and ultimately its conversion to a fully differentiated phenotype in the liver and biliary system (Figure 2 ).
In the stomach, it is believed that stem cells (multipotent progenitor cells) are present in the proliferative cell zone in the isthmus region of the gastric glands, giving rise to all the various cell types by differentiation in a bipolar manner, so that gastric glands are monoclonal in the adult stage (Karam, 1999; Brittan and Wright, 2002) . In pyloric mucosa, surface mucous cells move upward, while pyloric gland cells migrate downward. The intestinal epithelium folds into undulating proliferative crypts and the differentiated villi, pseudostratified epithelium into a single-layered epithelium occurs around embryonic day 14.5-18.5 (E14.5-18.5) in a wave that progresses from stomach to colon (Sancho et al., 2003; Radtke and Clevers, 2005; Stainier, 2005) . Simultaneously, the surrounding splanchnic mesoderm differentiates into smooth muscle and connective tissue. New cells are constantly added in the crypts and removed by apoptosis upon reaching the villus tips a few days later (Simon and Gordon, 1995; Marshman et al., 2002) . Stem cells and Paneth cells at the crypt bottom escape this flow (Ganz, 2000) . Studies using 3 H-labeled thymidine or bromodeoxyuridine labeling during early postnatal life or after irradiation indicate that small intestinal stem cells reside at position þ 4, the fourth cell position counting from the crypt bottom, (Paneth cells occupy the very bottom positions 1-3). In the distal colon, the stem cells are found at the bottom of crypt. The proximal colon stem cells rise to position þ 4 despite the absence of paneth cells (Potten and Loeffler, 1990) (Whitehead R, personal communication) .
While these epithelial stem cells self-renew throughout life, they are predominantly quiescent, and produce a progenitor/transitional cell type that proliferates extensively filling the crypts. After three to four cell divisions, these transitional cells proliferate and differentiate into one of the mature cell lineages, and migrate upward to the villus (in the small bowel, and the bottom two-thirds of the colonic crypts) with a final lifespan of about 4 days. Interestingly, the large bowel is 70 times more susceptible to cancer than the small bowel: The differential gradient of TGF-b paneth cells, ephrins potentially presenting as protective factors. Studies have localized TGF-b type II receptors to both differentiated epithelial cells of the villi (Barnard et al., 1989) as well as undifferentiated crypt cells (Koyama and Podolsky, 1989) . In polarized cells, the type II receptor is localized to the basolateral aspect, whereas ligand expression is mostly at the apical surface (Murphy et al., 2004) and at the villi. Smad4 and ELF expression is observed at both tips as well as the crypts (Figure 3 ). However, many interesting issues remain unresolved. These include the mechanism by which TGF-b signaling regulates so many different aspects of stem cell biology: from its role in stem cell conversion to progenitor/ transitional cells as well as the proliferation/differentiation switch in intestinal crypts and subsequent migration of the differentiated cells. It is likely that in the crypts, TGF-b signaling is important in transitioning from a stem cell into a proliferative progenitor phenotype. At the villus tips, TGF-b signaling may be required for apoptosis, thus maintaining the normal size, shape, and function of the polarized gut epithelium. The intestinal epithelium consists of four main cell types. Enterocytes absorb nutrients and secrete enzymes that help digest sugars and proteins. The most abundant cells are goblet cells that secrete protective mucus. Enteroendocrine cells are less commonly found and secrete hormones such as gastrin, secretin, cholecystokinin, serotonin, and substance P. Paneth cells secrete antimicrobial peptides such as defensins (cryptdins), as well as enzymes such as lysozyme and phospholipase A2, and live for about 20 days. Specialized myoepithelial fibroblasts are crucial for the formation of the cypt/stem cell niche, and form a sheath along the intestinal tract. One to six stem cells reside in each crypt, divide once a day, and thus render the gut extremely sensitive to the effects of luminal carcinogens, chemo and radiotherapy. The rapid self-renewal rate in the gut is a powerful component of its high susceptibility to malignant transformation. The molecular mechanisms that control homeostatic self-renewal and those that underlie colorectal cancer (CRC) are remarkably conserved. Here, we discuss the biology of the intestinal epithelium, emphasizing the roles played by the TGF-b signaling pathway in epithelial self-renewal and cancer. This stem cell microenvironment or niche may act to maintain stem cell quiescence for decades. However, these cells are highly dynamic and, once activated, are converted to a fragile rapidly proliferating transitional/progenitor cell such that the intestine has the capacity to regenerate rapidly and constantly, and the liver can recreate itself in a few days after partial hepatectomy.
Capacities for tissue contributions across germ layers in the gut
Adult intestinal stem cell plasticity involves stem cell differentiation largely determined by different microenvironments while trafficking from the bloodstream (Blau et al., 2001) . The role of the microenvironment in stem cell differentiation has been described by a number of studies demonstrating expression of donor-derived genetic markers in nonhematopoietic cells within the intestinal epithelium (Krause et al., 2001) , liver parenchyma (Petersen et al., 1999; Lagasse et al., 2000; Theise et al., 2000; Krause et al., 2001; Vassilopoulos et al., 2003; Wang et al., 2003) , pancreas (Ianus et al., 2003) , and other tissues (Krause et al., 2001; Theise and Krause, 2002) . Cell transdifferentiation and cell-cell fusion are potential mechanisms by which stem cells could contribute to cell types of different lineages. Cell fusion has recently been implicated in the contributions of transplanted BM cells to the liver hepatocyte, cardiac myocyte, and Purkinje neuron populations Alvarez-Dolado et al., 2003; Vassilopoulos et al., 2003; Wang et al., 2003; Weimann et al., 2003) . In adult animals, experiments using cytogenetic and genetic markers have clearly demonstrated that the capacity of transplanted BM cells to regenerate functional hepatocytes in a mouse model of hereditary tyrosinemia type I relates to the ability of BM-derived cells to fuse with cells in the livers of the recipient mice (Vassilopoulos et al., 2003; Wang et al., 2003) . Half of the small cell dysplastic foci, the earliest precursor lesions known to date, consist of progenitor cells and their progeny, suggesting that these lesions are the result of activation and proliferation of progenitor cells (Libbrecht et al., 2000 (Libbrecht et al., , 2001 . These results suggest that in human liver both dedifferentiation of mature hepatocytes and maturation arrest of progenitor cells may lead to hepatocellular carcinoma in humans.
Microenvironment exerts control over the genome in both normal and malignant cells TGF-b signaling promotes growth and development during early embryogenesis and in some adult mesenchymal cells. In mature tissues, however, many cells respond to TGF-b with cytostasis and, in some cases, with apoptosis. Epithelial, endothelial, hematopoietic, and neural progenitor cells, as well as certain mesenchymal cell types are programmed for these types of TGFb responses. The delicate equilibrium maintained by the normal microenvironment for functional differentiation (Bissell, 1981) has been shown in experiments using chimeric mice and in chickens, where wound induced TGF-b was found to be responsible for tumors that formed in adult chickens, dependent on the puncture wound at the injection site or at distally wounded sites (Dolberg et al., 1985; Sieweke et al., 1990) . Thus, neighboring cells can be pivotal in tumorigenesis. This stromal component is highlighted by the interaction between fibroblasts and epithelial cells resulting in invasive squamous cell carcinoma (SSCA) of the forestomach. Stromal fibroblasts unresponsive to TGF-b generated HGF and this abnormal paracrine signaling lead to epithelial tumors (Bhowmick et al., 2004; Radisky and Bissell, 2004) . Furthermore, stromal defects occur in a number of hereditary gastrointestinal cancers such as juvenile polyposis, where Smad4 and BMP2R mutations account for over 30% of cases (Jacoby et al., 1997; Howe et al., 1998) . In these examples, the TGF-b pathway acts as a powerful tumor suppressor, even in the presence of strong oncogene expression (Sternlicht et al., 1999) .
It is likely that a dynamic link exists between cells in the gut and their microenvironment that maintains normal homeostasis. Once this is disrupted, genetically damaged gut cells utilize this reciprocal relationship and modify their environment, which in turn brings about more pathological behavior from the cells (Bissell et al., 1982) . Ultimately, it is this deleterious relationship that may result in cancer many years later.
TGF-b in cancers of the gastrointestinal tract
Several factors may account for the tissue-specific potential of each cancer gene, and while many have been identified in gastrointestinal cancers, identifying new factors remains a constant and important challenge. Once the first tumorigenic event is in place, further tumor progression will depend on the nature of the initiating event and the developmental stage of the cell that sustained it, as well as additional mutations that must occur. For example, colon cancers initiated by a germline mutation in adenomatous polyposis coli (APC) progress differently than colon cancers initiated by germline mutation in genes that repair replication errors (Massague, 2004) . In total, 5-10% of CRC cases are inherited in an autosomal-dominant fashion (Lynch and de la Chapelle, 2003) . These hereditary cancer syndromes are often divided into two main categories: hereditary nonpolyposis CRC (HNPCC) and familial adenomatous polyposis (FAP). HNPCC is characterized by instability of microsatellites (repeats of short DNA sequences) (Fodde et al., 2001) , and can be caused by mutations in mismatch repair genes, such as MSH2 and MLH1 (Huang et al., 1996) , termed the caretakers of genome integrity (Leach et al., 1993; Thibodeau et al., 1993; Bronner et al., 1994; Kinzler and Vogelstein, 1998) . It is believed that these DNA repair defects lead to transformation through mutations in genes such as APC. A crypt and its associated villus can be viewed as the smallest self-renewing unit from which the epithelium is built. The position along the crypt-villus axis defines the various stages in the life of an epithelial cell. TGF-b signaling is intimately linked with the biology of the intestinal epithelium. This first became clear when Smad4, originally identified as a tumor suppressor gene in the pancreas, was recognized as a key negative regulator of the cascade. It is likely that G1 cell cycle progression and cell proliferation are limited by extracellular signals that maintain tissue homeostasis by cytokines such as the TGF-b and Wnt family (Shi and Massague, 2003) .
Constant proliferation of stem cells is a vital component in gastrointestinal tissues. In these renewing tissues, mutations will most likely result in expansion of the altered stem cells, perpetuating and increasing the chances of additional mutations and tumor progression. This provides a rationale for targeting tumor stem cells as being the most effective way to treat cancers such as colon cancer. About 50% of the Western population develops an adenomatous polyp by the age of 70, a key step for cancer formation (Fearon and Vogelstein, 1990; Jemal et al., 2002) . These ideas have drawn attention to the pathways that control stem-cell proliferation. Among these, the TGF-b, Myb, Wnt, and Hedgehog pathways are of particular relevance to cancer. These pathways feature prominently in cell-fate specification and pattern formation during embryogenesis and adult tissue renewal. The proliferative effect of both pathways involves the transcriptional induction of Myc. Mutations that constitutively activate the Wnt pathway are essentially universal in colon cancer (Fearon and Vogelstein, 1990; Kinzler and Vogelstein, 1998) . Inherited mutations that inactivate APC are responsible for familial adenopolyposis, a highly penetrant cancer predisposition syndrome. Inactivation of both APC alleles is observed in most colon cancers (Figure 4) . TGF-b can induce antiproliferative gene responses at any point during the cell division cycle, although most effective inhibition of cell cycle progression occurs during G1. Two classes of antiproliferative gene responses are involved in TGF-b-mediated growth arrest: gene responses that inhibit cyclin-dependent kinases (cdks) and downregulation of c-myc. Arrested cells in the G1 phase have reduced expression of cdk2, cdk4, cyclin D2, cyclin D3, and cyclin A (Grana and Reddy, 1995; Sherr, 1996; Poon et al., 1997) . Modulation of cell cycle progression by TGF-b signaling occurs predominantly by Smad proteins (Attisano and Massague et al., 2000; Hu and Zuckerman, 2001; Liu et al., 2004) . Recruitment of Smads to the receptor and consequent activation is regulated by adaptor molecules, ubiquitination as well as acetylation (Shi and Massague, 2003) . The TGF-b cytostatic programme in epithelial cells results in p21Cip1 and p15Ink4b expression with concomitanat Id as well as Myc repression . Once p21Cip1 is relieved from Myc-mediated repression, it is transactivated by a SMAD-FOXO complex (Seoane et al., 2004) . FOXO transcription factors (FOXO-1, -3, -4, and -6) are members of the Forkhead family involved in growth, development, and longevity (Accili and Arden, 2004) . Akt binds to FOXG1, and thus inhibits the activity of FOXO factors as SMAD partners (Tran et al., 2003) . TGF-b-mediated apoptosis involves induction of the death-associated protein kinase DAPk and the inositol-5-phosphatase SHIP, which limits Akt survival signaling (Cohen and Frame, 2001 ). Cancer cells possess multiple escape routes from the cytostatic responsiveness to TGF-b Massague, 2004) . Indeed, inactivating mutations in the TGF-b type-II receptor are very common in colon cancers with defects in replication-error repair. Inactivation of Smad4 (also known as DPC4, deleted in pancreatic carcinoma locus 4) occurs in one-half of pancreatic carcinomas. However more often, tumor cells lose cytostatic responsiveness because of defects downstream of SMAD. In such cases, tumor cells may use other aspects of TGF-b signaling, thereby exacerbating their own proliferative, invasive, and metastatic behavior. TGF-b can thus switch from a tumor suppressor into a tumor instigator (Derynck et al., 2001) . Colon carcinoma is largely delineated by a sequence of events inducing alterations in morphogenesis, the adenoma-carcinoma sequence. The earliest identifiable lesion is an aberrant crypt focus, a small dysplastic lesion in the colonic epithelium, in which mutant cells at the surface epithelium of the colon spread laterally and downward to form new crypts (Shih et al., 2001) . Alternatively, these adenomas could grow initially in a bottom-up pattern (Preston et al., 2003) . Aberrant crypt foci expand over time to form macroscopically visible adenomatous polyps. The transition from benign (adenoma) to malignant growth (carcinoma) is believed to be progressive. Adenomas first advance to the carcinoma in situ stage. Overtly invasive carcinomas often represent the first clinical presentation of colorectal tumors. Little is known about the genetic alterations and precise mechanisms driving progression from early stage in situ carcinomas through the successive clinically defined stages of regional invasion and distant metastasis. These mechanisms are just beginning to be defined in mouse models for adenoma formation, an early event in the progression to colon cancer that identifies a tumor suppressor role for the TGF-b adaptor protein ELF as well as common mediator Smad4. ELF in human CRC correlates with Smad4 expression and in the abnormal gut phenotypes, as a bspectrin, is important in conferring cell polarity and maintaining cell architecture. Labeling with anti-ELF, and anti-Smad4 on normal human colon tissue controls and 21 CRCs reveal similar patterns of ELF and Smad4 expression. Further analysis of the role of ELF in human CRC confirm reduced ELF expression in Dukes B1 stage tissues, and with Smad4 in advanced colon cancers. In the mouse mutant model, three out of 19, 6-8-month-old elf
þ /À mutant mice developed colonic adenomas (cecum and ascending colon) compared to none in wild-type controls or in Smad4 þ /À mutant mice. Analysis of development of colon cancer in elf
þ /À mutant mice pinpoints the defect to hyperplasia/adenoma transition identifying that the mechanism involves an inability to maintain epithelial cell polarity and thus tissue architecture. Loss of ELF expression in early cancer stages implies its potential role as a predictor in detecting early colon cancers. Interestingly, loss of ELF combined with loss of Smad4 expression seen in advanced CRC indicates poor prognosis. This indicates a strong role for ELF in TGF-b signaling in the suppression of early colon cancer, as well as later through Smad4 in metastatic disease (Figures 3 and 4) .
TGF-b signaling, Wnt signaling, FAP, and CRC
FAP patients carry in their colon numerous florid adenomatous polyps, which are defined as benign epithelial neoplasia (polyps) built from glandular elements (adenomatous) (Haggitt and Reid, 1986) . Owing to the polyp burden, FAP patients invariably develop CRC around the age of 40. FAP patients carry one mutant copy of the tumor suppressor gene APC in their genome (Groden et al., 1991) . APC is not only mutated in the hereditary FAP syndrome, but somatic APC mutations also occur in the vast majority of sporadic adenomas and adenocarcinomas (Powell et al., 1992; Nagase and Nakamura, 1993) . The earliest identifiable lesion in the adenoma-carcinoma sequence (Fearon and Vogelstein, 1990) , the aberrant crypt focus, already bears detectable APC mutations (Nucci et al., 1997) , implying that loss of APC function represents the initiating event in sporadic CRC. Taking these observations together, APC appears to be the key gene, the gatekeeper, in the molecular pathogenesis of most sporadic and hereditary forms of CRC.
On the basis of the determination of the TGF-b target gene program in human CRC, we propose the following scenario (Barnard et al., 1989; Engel et al., 1999; Tang et al., 2005) . In crypt stem cells, Wnt signaling drives the formation of b-catenin/Tcf4 complexes, thus imposing a proliferative phenotype onto crypt epithelial cells. The linear migration, differentiation and compartmentalization along the crypt-villus axis itself is controlled by TGF-b and Wnt gradients, as well as other factors, beginning at the crypt bottom and translated through TGF-b control of cell polarization proteins in the large bowel , as well as Wnt-controlled expression of the EphB sorting receptors in the small bowel (Batlle et al., 2002) . The presence of TGF-b signaling and the absence of Wnt signaling in the villus compartment result in rapid cell cycle arrest and differentiation. Thus, Smad4 and Tcf4 constitute a dominant switch between the proliferative progenitor and the transitional progenitor or differentiated epithelial cell. At all stages of CRC, this switch is permanently reversed, because TGF-b signaling is inactivated whileTcf4 is constitutively activated by mutations in the Wnt cascade, leading to aberrant cypt foci and the longlived adenomatous polyps.
Recently, emerging data suggest crosstalk between the Wnt and TGF-b pathways. As described above, the TGF-b family of cytokines is capable of promoting growth or cell cycle arrest in different cell types. The predominant influence on normal intestinal epithelial cells is one of growth inhibition. Under normal conditions, TGF-b forms a complex with serinethreonine kinase receptors type I (TbRI) and II (TbRII). The constitutively active TbRII phosphorylates TbRI, which in turn phosphorylates one of the receptoractivated Smads (R-Smads). The active R-Smad will heterodimerize with the common mediator Smad, Smad4, and the two translocate to the nucleus where they drive transcription of target genes. These target genes include the TGF receptor TbRII, p21 cip1/waf1
, and p53. Of note, p21 cip1/waf1 induces differentiation in CRC cells (Rorke et al., 2000) . Also of note are the inhibitory Smads, Smad6, and Smad7, which are also among the genes activated by TGF-b signaling as part of a negative feedback mechanism (Nakao et al., 1997 (Nakao et al., , 2002 . Owing to its preference for growth inhibition in the intestine, members of the TGF-b signaling pathway are targets for disruption in colorectal carcinogenesis (Fearon and Vogelstein, 1990) . Most commonly mutated is TbRII, followed by Smad2 and Smad4 (Grady, 1998; Massague et al., 2000) .
The first characterized interaction between Wnt and TGF-b pathways was the construction of a complex between Lef-1 and b-catenin along with Smad4 on the Xenopus homeobox gene promoter, Xtwn (Labbe et al., 2000) . Synergy was demonstrated between the two transcription factors by using a Lef-1-Gal4 construct, which activated Gal4-luciferase vectors to a greater extent in the presence of Smad4 when compared to its activity alone. Axin has also been shown to play a role in Smad3-mediated signaling by associating with Smad3 in the cytoplasm and facilitating phosphorylation by TbRI/II, then disassociating when phospho-Smad3 associates with Smad4 (Furuhashi et al., 2001) . Interactions between the inhibitory Smad7 and b-catenin have been demonstrated by immunoprecipitation studies in transiently transfected cells (Satterwhite and Neufeld, 2004; Edlund et al., 2005) . TGF-b cells stably transfected with inducible Smad7 result in increased bcatenin, Lef1, and c-Myc expression. This increase in Lef1 and c-Myc expression is dependent on Smad7. Thus, it is predicted that a complex with Smad7, bcatenin, and Lef1 forms in response to TGF-b signaling, and the resulting complex may be responsible for driving c-Myc and Lef1 production. Remarkably, TGF-binduces redistributions at b-catenin, a phenomenon that requires Smad7. Smad7 also acts as a scaffold protein in the activation of the TGF-b-Tak1-Mkk3-p38 MAP kinase pathway, and is required for p38 activation. In other experiments, the presence of p53 and its Smad7-dependant activation are shown to be required for TGFb-mediated redistribution of b-catenin.
Another link in the pathway is AKT, which is phosphorylated/activated by p38, and in turn can phosphorylate and deactivate GSK-3b at serine 9. Blots from cells treated with TGF-b showed an increase in pAkt s473 as well as an increase in pGSK3b s9, while the total levels of both proteins remained unchanged. In the absence of Smad7, no increase in activated Akt or inactivated GSK3b was seen. Inhibition of p38 prevented activation and inhibition of Akt and GSK3b, respectively, as did inhibition of PI3K to an even greater extent. Finally, to determine the effect of this TGF-bSmad7 dependent b-catenin signaling on apoptosis, siRNA specific to b-catenin was used to effectively knockdown b-catenin. Cells treated with b-catenin siRNA showed effective knockdown of b-catenin and were protected from TGF-b induced apoptosis. On the basis of this data, the authors propose a mechanism by which TGF-b signaling, dependant on Smad7, activates p38 MAP Kinase, which in turn activates AKT to inhibit GSK3b, allowing accumulation of b-catenin. bcatenin then builds up in the cytoplasm and translocates to the nucleus where it partners with LEF1 and Smad7 to promote apoptosis. Further study of gene expression driven by this Smad7-b-catenin complex will undoubtedly prove valuable in the understanding of this b-catenin-mediated apoptotic pathway.
Canonical Wnt signaling maintains the growth of stem cells, the continued passage into intestinal progenitor cells, and unfortunately in many cases, it drives the growth of CRC. Yet the TGF-b pathway may employ b-catenin, one of Wnt's chief effectors of proliferation, in a pathway promoting apoptosis. These effects may render the TGF-b signaling pathway a consistent target in colorectal carcinogenesis -as an unleashed Wnt pathway stabilizes b-catenin, the antigrowth/proapoptotic pathways of TGF-b may be amplified, making for increased selective pressure for inactivating mutations within the TGF-b pathway.
TGF-b pathway inactivation in gastrointestinal cancer
Despite a widespread inactivation of the TGF-b pathway in gastrointestinal tumors, only a fraction of sporadic tumors exhibit inactivating mutations in early tumor formation, suggesting that other mechanisms play a critical role in the inactivation of this pathway. Indeed, the functions of TGF-b are more complex than simply inhibiting cell growth, as TGF-b can induce the growth of mesenchymal cells, alter synthesis of extracellular matrix components as well as metalloproteases involved in cell invasion (Sporn and Roberts, 1990; Tang et al., 2003) . TGF-b signals also modulate the immune response to tumors, and are thought to play a role in tumor angiogenesis (Shi and Massague, 2003) . It has been estimated that nearly all pancreatic cancers (Goggins et al., 1998; Villanueva et al., 1998) and colon cancers (Grady et al., 1999) have mutations disabling a component of the TGF-b signaling pathway. Some of these mutations occur in the TGF-b receptors, Smad4 or Smad2, or in the BMP family such as BMP2R; others may occur in untested or unknown components of the signaling pathway .
Genetic studies in mice have provided strong models and further evidence for the role of TGF-b in tumor suppression in early stages. TGF-b1 heterozygous null mice show increased hepatocyte proliferation and decreased apoptosis in the liver, with overt tumor formation upon challenge with carcinogens (Tang et al., 1998) . Smad-deficient mice display phenotypes in support of a tumor suppressor role for the Smads. Although mice with homozygous loss of Smad2 and Smad4 die in utero, their heterozygous counterparts are viable (Yang et al., 1998; Weinstein et al., 2001) . In fact, mice heterozygously null for Smad4 develop gastric polyps that can develop into tumors at a late age (Taketo and Takaku, 2000; Xu et al., 2000) . Furthermore, mice defective in APC develop numerous indolent intestinal polyps. When mice with one mutated APC allele are crossed with heterozygous null Smad4 mice, the compound heterozygotes develop larger polyps that can progress into malignant adenocarcinomas with loss of the remaining copies of both APC and Smad4 (Takaku et al., 1998) . Moreover, although no Smad3 mutation has been found in human cancer, mice with a homozygous deletion of Smad3 develop aggressive CRC at an early age in a manner that seems to be highly dependent on the genetic background of the mice (Thiagalingam et al., 1996; Zhu et al., 1998) . Smad activity is modulated by a number of cofactors, such as ELF, SARA, Filamin, and microtubules that also functionally interact with multiple other signal transduction pathways (Tsukazaki et al., 1998; Dong et al., 2000; Tang et al., 2003) . Adaptor proteins such as SARA and ELF play a critical role in the proper control of Smad access to the receptors for activation at the cell membrane and for facilitating TGF-b functions such as growth, differentiation, and cell fate specification. This is also evidenced by our observation that ELF (a bspectrin) disrupts TGF-b signaling as a result of mislocalization of Smad3 and Smad4 (Tang et al., 2003) . Multiple defects are seen in the elf À/À mutants, the majority dying at E11.5 with gut, liver, cardiovascular, and neural defects. Aberrant gut lumen formation is seen in the elf À/À mutant embryos, the lumen appearing either distorted or without normal luminal columnar cells, the cells lining the lumen being flattened and no longer appearing organized. Studies in elf À/À mutants indicate that while lineage is established, earlier, aberrant differentiation occurs and subsequent growth may be arrested, resulting in organs of a smaller size with marked and abnormal phenotype most prominently seen in the brain, pancreas, and heart as well as an abnormal gut.
Tgf-b
À/À mutant mice that live to adulthood develop colon cancer by 5 months of age, preceded by precancerous lesions with inflammation and hyperplasia (Xu et al., 2000) . Smad4 deficiency in the Apc D716 mouse increases adenoma size and promotes cancer progression (Engel et al., 1999) . Disruption of ELF results in a similar phenotype, with elf
þ /À mice developing right-sided colonic polyps and defects in cellular architecture and polarization . Smad4 þ /À heterozygote mice develop inflammatory gastric polyps and tumors at about 12 months, with loss of the wild-type Smad4 allele (Xu et al., 2000) . Tumors show moderate stromal cell proliferation, infiltration by eosinophils and plasma cells, as well as foci of adenocarcinoma with signet ring cells. In this model, mutations in genes such as K-Ras, H-Ras, NRas, p53, or PTEN are not seen. Both elf À/À mice and Smad2
þ /À mice die in midgestation from gastrointestinal, liver, neural, and heart defects. Intercrosses between Smad4 þ /À with elf þ /À mice demonstrate that all elf þ /À /Smad4 þ /À mice (6/6, ages 7-9 months) exhibit widespread, markedly hyperplastic gastric glandular epithelium, with two foci of adenocarcinoma. In contrast, Smad4 þ /À mice (ages 4-23 months) develop gastric glandular hyperplasia more slowly, but more numerous and varied neoplasms, many at younger ages. These included SCCA in six, four arising from oral mucosa or skin and riddling the mandible or skull, and one each stomach and parotid duct; duodenal polyps (tubular adenomas) in four; adenocarcinomas in stomach and lacrimal gland (one each); and one lymphoma (cervical node). Smad3 þ /À (1/4) and Smad4 þ /À (4/16) mice developed abscesses of the skin, urogenital tract, and lacrimal glands. Heterozygous inactivation of elf and Smad4 causes an exacerbated phenotype of hyperplasia and adenocarcinoma of gastric epithelium, but not the SCCA, duodenal polyps, or abscesses seen in the other mice . These observations suggest a specific interaction of ELF and Smad4 in the genesis of gastrointestinal and other tumors.
Studies have firmly established a mouse model for gastric cancer in the Smad4 heterozygous mice. Smad4 heterozygous mice develop cancers in the gastric fundus and antrum when they are over 11 months old, and in the duodenum and cecum in older animals at a lower frequency (Taketo and Takaku, 2000; Xu et al., 2000) . With increasing age, polyps in the antrum show sequential changes from hyperplasia to dysplasia, carcinoma in situ, and finally invasion. These alterations initiate a dramatic expansion of the gastric epithelium where Smad4 is expressed. However, loss of the remaining Smad4 wild-type allele is detected only in later stages of tumor progression, suggesting that haploinsufficiency of Smad4 is sufficient for tumor formation. Smad2, 3, 4 and adaptor proteins such as ELF, a b-Spectrin are crucial for gastrointestinal development (Xu et al., 2000; Yang et al., 2005) . Gene dosage is critically important in this family as haploinsufficiency phenotypes result in holoprosencephaly, liver hypoplasia as well as gastric and colon carcinoma. Aberrant expression of b-G Spectrin has been described in multiple tumors (Younes et al., 1989; Sormunen et al., 1999) . As spectrin has been shown to be involved in the generation of cell polarity and protein sorting (Beck and Nelson, 1996; De Matteis and Morrow, 2000; Bennett and Baines, 2001) , it is conceivable that abnormalities in spectrin function could result in the partial or complete loss of cellular polarity seen in tumor cells. Similarly, ELF by virtue of its involvement in Smad4 localization and activation may act as a tumor suppressor, with aberrations in this interaction resulting in tumorigenesis.
On the other hand, TGF-b exacerbates the malignant phenotype of transformed and tumor-derived cells. High levels of TGF-b expression are correlated with advanced clinical stage of the tumor (Reiss, 1997; Gold, 1999) . Tumor-derived TGF-b could contribute to tumor growth indirectly by suppressing immune surveillance or stimulating production of angiogenic factors. However, TGF-b can also act directly on cancer cells to foster tumorigenesis. Tumor cells that have selectively lost their growth-inhibitory responsiveness to TGF-b but retain an otherwise functional TGF-b signaling pathway may exhibit enhanced migration and invasive behavior in response to TGF-b stimulation (Cui et al., 1996; Oft et al., 1998) . TGF-b signaling could promote tumor cell metastasis by inducing an epithelial to mesenchymal transition (EMT) in these cells (Oft et al., 1998) . EMT is characterized by the decrease in proteins involved in cell-cell adhesion, such as E-cadherin and increase of Vimentin and proteins involved in cell-extracellular matrix associations, ultimately leading to enhanced migratory and invasive properties of the cell. A switch from an epithelial to fibroblastoid phenotype occurs frequently during late stages of carcinoma progression and correlates with the metastatic potential of tumor cells (Tang et al., 2005) .
TGF-b receptor mutations in cancer
Inactivating mutations in TbRII may be present in as many as one quarter of all colon cancers and occur in most human colorectal and gastric carcinomas with microsatellite instability (MSI) Akiyama et al., 1997; Takenoshita et al., 1997; Grady et al., 1999) . A reduction in tumorigenicity and restoration of TGF-b-mediated growth arrest were seen in a human MSI colon cancer cell line stably transfected with wild-type TbRII and a human gastric cancer cell line (Chang et al., 1997) . MSI is commonly seen in many sporadic gastrointestinal cancers and results from DNA mismatch repair (MMR) defects, causing nucleotide additions or deletions in microsatellites, simple repeated sequences, throughout the genome. Thus, a frameshift and a truncated, inactive TbRII product occurs from MMR in one such microsatellite, a 10 bp polyadenine repeat within the TbRII sequence encoding a part of the extracellular domain (the BAT-RII track) . BAT-RII inactivating mutations are also found in colorectal and gastric tumors from patients with HNPCC, a familial cancer syndrome in which affected individuals inherit defects in genes encoding components of the DNA MMR pathway (Lu et al., 1996; Akiyama et al., 1997) and are specific for tissue origins, not being seen in the other tumors associated with this syndrome.
Most commonly, BAT-RII mutations are biallelic, but mutation in one allele may also be accompanied by a non-BAT-RII mutation inactivating the kinase domain in the other allele Parsons et al., 1995) . Missense mutations of TbRII, mostly targeting the kinase domain, have been reported in 15% of microsatellite stable colon cancers examined (Grady et al., 1999) . In addition, deletions of TbRI occur at a low frequency in pancreatic and biliary carcinomas (Goggins et al., 1998) . Interestingly, homozygosity of a common germline polymorphism, TbRI(6A), is associated with an increased incidence of colon cancer (Pasche et al., 1999) .
Smad mutations in cancer
The TGF-b signaling network is also disrupted in cancer by mutations in Smad4 and Smad2. Smad4, initially identified as DPC4 (deleted in pancreatic carcinoma locus 4) located on 18q21, undergoes biallelic loss in one half of all of pancreatic cancers Miyaki et al., 1999) , one-third of metastatic colon tumors (Goggins et al., 1998; Derynck et al., 2001) , and smaller subsets of other carcinomas. In addition, germline mutations in Smad4 are seen in patients with juvenile polyposis syndromes (JPSs), an autosomal dominant disorder characterized by hamartomatous intestinal polyps and an increased risk of gastrointestinal cancers (Howe et al., 1998) . Occasionally, Smad4 mutations as well as TbRI mutations have been found in biliary cancer (Hahn et al., 1998) and with TbRII mutations in colon cancer. Smad4 and the TGF-b receptors may therefore have certain nonoverlapping tumor suppressive activities. Smad2, also located on 18q21, is the target of inactivating mutations in a small proportion of CRCs (Eppert et al., 1996) . Inactivation of Smad2 and Smad4 occurs through the loss of the entire chromosome region, or by small deletions, frameshift, nonsense mutations, or missense mutations. Missense mutations mostly occur at the MH2 domain, with subsequent disruption of homo-and heterooligomerization of the Smads. Missense mutations in the MH1 domain of Smad2 and Smad4 can result in an enhanced autoinhibitory interaction between the MH1 domains with a decreases protein stability .
BMP signaling in gastrointestinal cancer
BMPs constitute the other half of signaling cytokines within the TGF-b superfamily. They regulate lineage and development, with signaling being mediated through Smad1, 5, and 8 (Shi and Massague, 2003) . Originally identified as molecules inducing cartilage and bone formation, they are expressed in multiple other mesenchymal tissues and signal to the adjacent epithelium. They are expressed in the stroma of villi, and phosphorylated Smad1, 5, and 8 are observed in differentiated villus epithelial cells (Haramis et al., 2004) . Mice mutant for the Bmpr1a gene develop a juvenile polyposis phenotype. In addition, inhibition of BMP signaling in the villus through the transgenic expression of the secreted BMP inhibitor noggin results in a JPS-like phenotype, including later development of adenomatous polyps (He et al., 2004) . Stromal BMP signals spatially position postnatal crypts adjacent to the intestinal wall. When BMP signaling is disrupted, crypts form anywhere in the epithelium, leading to the characteristic JPS histology and ultimately to hamartomas and adenomas.
The hamartomatous polyposis syndromes that include JPS are characterized by an overgrowth of mesenchymal tissues and are often attributed as defects in the landscape (Kinzler and Vogelstein, 1998) . JPS is an autosomal dominant hamartoma syndrome, in which patients have between 50 and 200 polyps, usually in the rectosigmoid region. Polyps are characterized by gross chronic inflammation and contain cystic spaces lined by a columnar epithelium and surrounded by abundant stroma (Rashid et al., 2000) . JPS patients have an increased risk of developing gastrointestinal polyps and CRC. Inactivating mutations in Smad4 (Howe et al., 1998) and BMP receptor type 1A (Howe et al., 2001; Zhou et al., 2001 ) account for up to 50% of JPS cases. Mutations in the gene for phosphatase and tensin homolog (PTEN) have been described in a few families with the primary loci for JP mapping to 18q21.1 and 10q22-23. In non-Smad4/PTEN mutation JPS families germline nonsense mutations in affected kindred members 10q22-23 for BMPR1A, a serine-threonine kinase type I receptor, were demonstrated indicating that loss of intestinal BMP signaling is the prominent cause of JPS and gastrointestinal cancers. Thus, in addition to the epithelial role of TGF-b, these studies also point to a role for the BMP pathway in epithelial/mesenchymal homeostasis.
Summary
Many emerging pathways interacting with the TGF-b superfamily are only now being described (Liu et al., 2004) . For instance, the mechanism whereby Smad4 mutations interfere with Smad activity is uncertain, and could be through E3 mediated ubiquitination of Smad4 complexes, by ubiquitinators ranging from SMURFS to PRAJA (Izzi and Attisano, 2004) . In addition, adaptor proteins such as SARA, Filamin, microtubules, and ELF are now seen to be prominent controllers of this pathway (Liu et al., 2004; Massague, 2004) . Activation of multiple other signaling pathways, particularly where the TGF-b pathway is inactivated in gastrointestinal cancers, now present important therapeutic options in difficult to treat gastrointestinal cancers that include pancreatic, gastric, and hepatocellular. For instance, HGF and c-met are activated in fore-gut cancers with inactivation of TGF-b signaling, suggesting these as targets for new therapeutics. These findings have led to the development of a number of small-molecule compounds targeting the TGF-b pathway, and where TGF-b pathway is inactivated, therapeutics aimed at activated receptor tyrosine kinases, their ligands or their degradative pathways. New anticancer drugs Cetuximab (Erbitux) raised against EGFR and bevacizumab (Avastin) against the angiogenic mitogen vascular endothelial growth factor (VEGF) are examples that are approved for the treatment of advanced and metastatic colon cancer. The small-molecule kinase inhibitor imatinib (Gleevec) is proving to be very effective against mutant kit in gastrointestinal sarcomas (Massague, 2004) . Many questions remain unanswered; these include the role of stem cell regeneration with respect to the complex environment of gut microbial flora. Perhaps, insight into the protective mechanisms at play in the small bowel, which render it far less susceptible to tumorigenesis than the large bowel, will bring forth new therapeutics for gut cancers. The elucidation of the complex tumor suppressor as well as tumorigenic role of the TGF-b signaling pathway, its stabilizing and differentiating effect on transitional/ progenitor cells in the gut should be pivotal for our optimization of therapeutics in hitherto poor prognosis cancers such as those of the liver, stomach, and pancreas.
